Facebook link Linked In link You Tube link

The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases.

Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001 and we look forward to seeing you at our 17th Annual Meeting in Chicago, Illinois!  

Visit the FOCIS 2017 microsite to view the program, register, book a room and more!


News & Information

2017 Lupus Insight Prize Call for Nominations Underway

The Lupus Research Alliance is pleased to announce that the Lupus Insight Prize nominations are now underway. The Lupus Insight Prize recognizes a major, novel insight and/or discovery with the promise of changing thinking about lupus as well as a high likelihood of generating further advances in the diagnosis and treatment of the disease. Deadlines and nomination guidelines are available through the proposalCENTRAL website at https://proposalcentral.altum.com. Once there search for the Lupus Insight Prize.

The Lupus Insight Prize recipient will be awarded $150,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment.

The full application must be submitted by the Nominator and the Candidate electronically by April 24, 2017 at 5 p.m. ET. All applications will be reviewed by members of an independent Selection Committee. Instructions on how to submit a nomination for the Lupus Insight Prize and the complete guidelines are available at www.LupusInsightPrize.org. The 2017 Prize will be awarded on June 15, 2017 at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting.

New Chilean Workshop Announced - FOCIS Goes South

We are glad to invite you to the first FOCIS course to be held in Santiago de Chile: "FOCIS goes South: Advances in Translational and Clinical Immunology" hosted by the Millennium Institute on Immunology and Immunotherapy (www.imii.cl), a recently incorporated FOCIS Excellence Center.

This workshop will be held this upcoming year 2017 on May 15-17th with excellent international and regional speakers.

The workshop will focus on immunological mechanisms and treatments in autoimmunity, cancer, inflammation and infectious diseases. This is a great opportunity for establishing and expanding collaborative networks in South America.

All Articles...

 Immuno-Oncology Research Tools from BioLegend

 FOCIS 2017 Sponsors

 Graphic of FOCIS 2017 Supporters


 Preview of the latest ePublication

ePub header 2016

May 15, 2017
EDITOR: Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital  EDITORIAL BOARD: Abul K. Abbas, MD, University of California, San Francisco | Carla J. Greenbaum, MD, Benaroya Research Institute | Andrew H. Lichtman, MD, PhD, Brigham & Women's Hospital

Highlights from Recent Literature

circlearrow2 Help Not Wanted in the Joint

NEW! The 'Highlights from Recent Literature' review articles are now published monthly on Science Immunology under the "Editor's Choice" article category.


  Reviewed by Andrew H. Lichtman, Brigham and Women's Hospital


Developments in Basic Immunology and Novel Therapies

circlearrow2 Adoptive Cell Therapy with CAR-T cells: Rationale, Promise and Challenges


The idea of treating cancer patients by giving them large numbers of tumor-specific immune cells has been an appealing strategy of cancer immunotherapy for over two decades. The initial approaches relied on isolating rare circulating or tumor-infiltrating T cells (and, in some cases, natural killer [NK] cells) from patients, expanding these cells in culture, and injecting them back into the patients. Such treatments were successful in eliminating tumors in some patients, principally melanoma, but the results have been variable and often disappointing. There are many possible explanations for the modest success of passive immunity conferred by T cells. One important reason may be that in the cell populations used, the frequency of T cells that are specific for the tumor is low, and most of the transferred cells are not doing what it was hoped they would do. In addition, recovery of tumor-specific T cells is higher from certain tumor types such as melanoma, and lower in other tumors, limiting source materials (1).


  Submitted by Abul K. Abbas, MD, and Jonathan H. Esensten, MD, PhD, University of California, San Francisco


Human Immunophenotyping Update

circlearrow2 Sample Saving Technologies and Chip Flow Cytometry

The ever-expanding number of biomarkers, the drive towards precision medicine, the increasing awareness of cellular heterogeneity, and the interest in rare subsets of cells have, in combination, led to a pressing need to be able to perform various assays on sample of limited sizes or of low cellularity. In general, this is being accomplished by performing multiple assays on a single sample (multiplexing) or miniaturizing the technologies and assays, or both.


  Submitted by J. Philip McCoy, Jr., PhD, NHLBI, National Institutes of Health

Selected Recent Clinical Trial Results

circlearrow2 Safety and Tolerability of an ANTI-CD19 MONOCLONAL Antibody, MEDI-551, in Subjects with Systemic Sclerosis: A Phase I, Randomized, Placebo-controlled, Escalating Single-dose Study

Clinical Trial: Schiopu E, Chatterjee S, Hsu V, et al. Arthritis Res Ther. 2016 Jun 07; 18(1):131

Disease: limited or diffuse cutaneous systemic sclerosis (SSc)

Intervention: MEDI-551, an anti-CD19 monoclonal antibody 


  Submitted by Sandra Lord, MD, Benaroya Research Institute. Edited by Carla J. Greenbaum, MD, Benaroya Research Institute